Investors Buy High Volume of Maravai LifeSciences Put Options (NASDAQ:MRVI)

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) saw some unusual options trading activity on Wednesday. Stock investors bought 1,002 put options on the stock. This represents an increase of 1,791% compared to the average daily volume of 53 put options.

Maravai LifeSciences Trading Down 0.9%

MRVI opened at $2.26 on Friday. Maravai LifeSciences has a fifty-two week low of $1.67 and a fifty-two week high of $10.03. The company has a debt-to-equity ratio of 0.89, a current ratio of 10.74 and a quick ratio of 9.94. The firm has a market capitalization of $575.53 million, a price-to-earnings ratio of -1.38 and a beta of 0.25. The company’s 50 day moving average price is $2.07 and its two-hundred day moving average price is $3.55.

Maravai LifeSciences (NASDAQ:MRVI) last posted its earnings results on Monday, May 12th. The company reported ($0.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.01). Maravai LifeSciences had a negative return on equity of 6.61% and a negative net margin of 81.13%. The business had revenue of $46.85 million for the quarter, compared to the consensus estimate of $44.01 million. Maravai LifeSciences’s revenue for the quarter was down 26.9% on a year-over-year basis. As a group, research analysts predict that Maravai LifeSciences will post -0.24 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages have recently commented on MRVI. Robert W. Baird dropped their target price on shares of Maravai LifeSciences from $3.00 to $2.00 and set a “neutral” rating for the company in a research report on Tuesday, May 13th. Morgan Stanley lowered their price objective on shares of Maravai LifeSciences from $7.00 to $5.00 and set an “equal weight” rating for the company in a research report on Tuesday, March 25th. Craig Hallum lowered their price objective on shares of Maravai LifeSciences from $12.00 to $10.00 and set a “buy” rating for the company in a research report on Tuesday, May 13th. UBS Group lowered their price objective on shares of Maravai LifeSciences from $8.00 to $2.50 and set a “neutral” rating for the company in a research report on Friday, March 21st. Finally, Bank of America lowered their price objective on shares of Maravai LifeSciences from $9.00 to $8.00 and set a “buy” rating for the company in a research report on Monday, March 3rd. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $6.64.

Institutional Investors Weigh In On Maravai LifeSciences

Institutional investors have recently modified their holdings of the company. ProShare Advisors LLC boosted its stake in shares of Maravai LifeSciences by 89.8% in the 4th quarter. ProShare Advisors LLC now owns 55,488 shares of the company’s stock valued at $302,000 after purchasing an additional 26,251 shares during the last quarter. Empowered Funds LLC bought a new stake in shares of Maravai LifeSciences in the 4th quarter valued at $155,000. Bleakley Financial Group LLC boosted its stake in shares of Maravai LifeSciences by 30.1% in the 4th quarter. Bleakley Financial Group LLC now owns 41,691 shares of the company’s stock valued at $227,000 after purchasing an additional 9,657 shares during the last quarter. Rhumbline Advisers boosted its stake in shares of Maravai LifeSciences by 9.9% in the 4th quarter. Rhumbline Advisers now owns 185,221 shares of the company’s stock valued at $1,009,000 after purchasing an additional 16,712 shares during the last quarter. Finally, KLP Kapitalforvaltning AS bought a new stake in shares of Maravai LifeSciences in the 4th quarter valued at $112,000. 50.25% of the stock is owned by institutional investors.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.